Contrasting effects of cardiac glycosides on cisplatin- and etoposide-induced cell death

Abstract Cardiac glycosides (CGs) or cardiotonic steroids, which constitute a group of naturally occurring compounds with a steroid-like structure, can act on Na+/K+-ATPase as a receptor and activate intracellular signaling messengers leading to a variety of cellular responses. Epidemiological studies have revealed that CGs, used for the treatment of cardiac disorders, may also be beneficial as anti-cancer agents. CGs, acting in combination with other chemotherapeutic agents, may significantly alter their efficiency in relation to cancer cell elimination, causing both sensitization and an increase in cancer cell death, and in some cases resistance to chemotherapy. Here we show the ability of CGs to modulate apoptotic response to conventionally used anti-cancer drugs. In combination with etoposide, CGs digoxin may enhance cytotoxic potential, thereby allowing the chemotherapeutic dose to be decreased and minimizing toxicity and adverse reactions. Mechanisms behind this event are discussed.

[1]  P. Bonaldo,et al.  Cardiac glycoside ouabain induces autophagic cell death in non-small cell lung cancer cells via a JNK-dependent decrease of Bcl-2. , 2014, Biochemical pharmacology.

[2]  H. Brismar,et al.  Calcium oscillations triggered by cardiotonic steroids , 2013, The FEBS journal.

[3]  P. Darcy,et al.  Immune modulation of the tumor microenvironment for enhancing cancer immunotherapy , 2013, Oncoimmunology.

[4]  R. Kiss,et al.  Cardiotonic Steroids-Mediated Na+/K+-ATPase Targeting Could Circumvent Various Chemoresistance Pathways , 2013, Planta Medica.

[5]  U. Jaehde,et al.  Contribution of intracellular ATP to cisplatin resistance of tumor cells , 2013, JBIC Journal of Biological Inorganic Chemistry.

[6]  B. Zhivotovsky,et al.  Autophagy in toxicology: cause or consequence? , 2013, Annual review of pharmacology and toxicology.

[7]  L. Galluzzi,et al.  Antineoplastic activity of ouabain and pyrithione zinc in acute myeloid leukemia , 2012, Oncogene.

[8]  Li-Yan Xu,et al.  Bufalin enhances the anti-proliferative effect of sorafenib on human hepatocellular carcinoma cells through downregulation of ERK , 2012, Molecular Biology Reports.

[9]  W. Chan,et al.  Bufalin induces autophagy-mediated cell death in human colon cancer cells through reactive oxygen species generation and JNK activation. , 2011, Free radical biology & medicine.

[10]  Zhong-wei Xu,et al.  Cardiotonic steroids attenuate ERK phosphorylation and generate cell cycle arrest to block human hepatoma cell growth , 2011, The Journal of Steroid Biochemistry and Molecular Biology.

[11]  C. Bortner,et al.  Ouabain-induced perturbations in intracellular ionic homeostasis regulate death receptor-mediated apoptosis , 2010, Apoptosis.

[12]  C. Riganti,et al.  Digoxin and ouabain induce P-glycoprotein by activating calmodulin kinase II and hypoxia-inducible factor-1alpha in human colon cancer cells. , 2009, Toxicology and applied pharmacology.

[13]  W. Berger,et al.  The Na+/K+-ATPase is the Achilles heel of multi-drug-resistant cancer cells. , 2009, Cancer letters.

[14]  J. Shapiro,et al.  Endogenous Cardiotonic Steroids: Physiology, Pharmacology, and Novel Therapeutic Targets , 2009, Pharmacological Reviews.

[15]  Jun O. Liu,et al.  Digoxin and other cardiac glycosides inhibit HIF-1α synthesis and block tumor growth , 2008, Proceedings of the National Academy of Sciences.

[16]  E. Diamandis,et al.  High-Throughput Screening Identifies Cardiac Glycosides as Potent Inhibitors of Human Tissue Kallikrein Expression: Implications for Cancer Therapies , 2008, Clinical Cancer Research.

[17]  W. Liu,et al.  Inhibition of the sodium/potassium ATPase impairs N-glycan expression and function. , 2008, Cancer research.

[18]  G. Scheiner-Bobis,et al.  Endogenous and exogenous cardiac glycosides: their roles in hypertension, salt metabolism, and cell growth. , 2007, American journal of physiology. Cell physiology.

[19]  K. Winnicka,et al.  Inhibition of DNA topoisomerases I and II, and growth inhibition of breast cancer MCF-7 cells by ouabain, digoxin and proscillaridin A. , 2006, Biological & pharmaceutical bulletin.

[20]  S. Azrak,et al.  Digitoxin, at concentrations commonly found in the plasma of cardiac patients, antagonizes etoposide and idarubicin activity in K562 leukemia cells. , 2006, Leukemia research.

[21]  M. Gheorghiade,et al.  Pharmacological treatment of chronic heart failure , 2006, Heart Failure Reviews.

[22]  A. Andres,et al.  Cardiac glycosides initiate Apo2L/TRAIL-induced apoptosis in non-small cell lung cancer cells by up-regulation of death receptors 4 and 5. , 2006, Cancer research.

[23]  K. Winnicka,et al.  Cardiac glycosides in cancer research and cancer therapy. , 2006, Acta poloniae pharmaceutica.

[24]  S. Azrak,et al.  Digitoxin inhibits the growth of cancer cell lines at concentrations commonly found in cardiac patients. , 2005, Journal of natural products.

[25]  Lijun Liu,et al.  Digitalis-Induced Signaling by Na+/K+-ATPase in Human Breast Cancer Cells , 2005, Molecular Pharmacology.

[26]  Elizabeth C. M. de Lange,et al.  Potential role of ABC transporters as a detoxification system at the blood-CSF barrier. , 2004 .

[27]  M. Tsujimoto,et al.  Digoxin up-regulates multidrug resistance transporter (MDR1) mRNA and simultaneously down-regulates steroid xenobiotic receptor mRNA. , 2003, Biochemical and biophysical research communications.

[28]  C. Teng,et al.  Cardiac glycosides induce resistance to tubulin-dependent anticancer drugs in androgen-independent human prostate cancer. , 2002, Journal of biomedical science.

[29]  A. Scovassi,et al.  Poly(ADP-ribose) polymerase-1 cleavage during apoptosis: An update , 2002, Apoptosis.

[30]  Zijian Xie,et al.  Na(+)/K(+)-ATPase as a signal transducer. , 2002, European journal of biochemistry.

[31]  R. Strick,et al.  Cation–chromatin binding as shown by ion microscopy is essential for the structural integrity of chromosomes , 2001, The Journal of cell biology.

[32]  H. Brismar,et al.  Ouabain, a steroid hormone that signals with slow calcium oscillations , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[33]  S. Tretli,et al.  Digitoxin medication and cancer; case control and internal dose-response studies , 2001, BMC Cancer.

[34]  R. Newman,et al.  Inhibition of export of fibroblast growth factor-2 (FGF-2) from the prostate cancer cell lines PC3 and DU145 by Anvirzel and its cardiac glycoside component, oleandrin. , 2001, Biochemical pharmacology.

[35]  A. Edelman,et al.  Drug resistance induced by ouabain via the stimulation of MDR1 gene expression in human carcinomatous pulmonary cells. , 2001, Cancer research.

[36]  L. Nutt,et al.  Cardiac glycosides stimulate Ca2+ increases and apoptosis in androgen-independent, metastatic human prostate adenocarcinoma cells. , 2000, Cancer research.

[37]  J. Haux.  Digitoxin is a potential anticancer agent for several types of cancer. , 1999, Medical hypotheses.

[38]  R. Arceci,et al.  Inhibition of N-linked glycosylation of P-glycoprotein by tunicamycin results in a reduced multidrug resistance phenotype. , 1995, British Journal of Cancer.

[39]  T. Lawrence,et al.  Dependence of etoposide-induced cytotoxicity and topoisomerase II-mediated DNA strand breakage on the intracellular ionic environment. , 1989, Cancer research.

[40]  T. Lawrence,et al.  The influence of Na+, K+-pump blockade on doxorubicin-mediated cytotoxicity and DNA strand breakage in human tumor cells , 2008, Cancer Chemotherapy and Pharmacology.

[41]  S. Fukushima,et al.  Role of Na+, K+-ATPase α1 subunit in the intracellular accumulation of cisplatin , 2005, Cancer Chemotherapy and Pharmacology.

[42]  L. Böhm,et al.  Na+, K+-ATPase inhibitor, ouabain accentuates irradiation damage in human tumour cell lines. , 1998, Radiation oncology investigations.